The Cell BriefAbout
Peptide and cell science, explained simply
One compound. One brief. Real studies.
What a brief is
Each brief takes one peptide or cell signal and explains it from the ground up: what it is, what it does in the body, what researchers have found in cells, animals and people, and where it stands today.
Briefs run 1,200 to 1,800 words, in plain language, with every technical term defined the first time it appears. Every claim links to the paper it came from, and the sources sit at the end of each brief.
How we read the research
Not all studies carry the same weight. We always say which kind of study a finding comes from.
The evidence ladder
- Human RCT randomized trials in people
- Human observational studies
- Animal mice, rats and other models
- Cell lab dish studies
Early research is exciting, and we say when something is early days. We describe what a study found, in what, and what is still unknown.
What we never do
Our lines
- No dosing, protocols or how-to-use guidance.
- No sourcing, sellers, prices or product links.
- No medical or treatment claims.
- No paid coverage. If that ever changes, it will be clearly labelled.
Editorial standards
Numbers, years and findings come from checkable, peer-reviewed sources, and each brief lists them. When a study is small, early, in animals or industry-funded, we say so. Regulatory status is stated plainly, in one line, where it matters.
If we get something wrong, tell us and we will fix it and note the change on the brief and in our corrections log. See also our methodology.
Contact
Questions, tips and corrections: hello@thecellbrief.com.
Education only. Not medical advice. The Cell Brief summarises published research for general education. It is not medical advice, and nothing here is a recommendation to use any compound.
One brief a week
One brief per compound. Unsubscribe anytime.